Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omidubicel vs Unmanipulated Cord Blood in Hematological Malignancies
NCT02730299Phase 3Completed
- Sponsor
- Gamida Cell
- Start
- Dec 2016
- Primary completion
- Apr 2021
- Modality
- Stem Cell Therapies
- Countries
- 10
01
Overview
A Phase 3 trial of omidubicel in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), lymphoma, sponsored by Gamida Cell. Started Dec 2016; status: completed.
02
Drugs
omidubicel
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)lymphoma
Beyond the preview
Go deeper on NCT02730299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02730299.